Document:

<PAGE>

                                                                    Exhibit 10.6

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                             COLLABORATION AGREEMENT
                                     BETWEEN
                     LIPOMED INC. OF RALEIGH, NC ("LIPOMED")
                                       AND
              BRUKER INSTRUMENTS, INC. OF BILLERICA, MA ("BRUKER")

LipoMed and Bruker wish to collaborate on the adaptation, further development
and deployment of Bruker's INCA(TM) (Integrated NMR Clinical Analyzer) for
LipoMed's NMR LipoProfile(R) clinical laboratory test for blood lipoprotein
levels.

As part of this Collaboration Agreement ("Agreement"), Bruker and LipoMed agree
as follows:

1.   A previously executed Confidential Disclosure Agreement, dated September
     14, 1998, shall be extended for the duration of the Agreement.

2.   LipoMed, including any subsidiaries or licensees of LipoMed, shall commit
     to the purchase of at least [**] INCA 400 MHz systems within [**] of the
     execution date of the Agreement. The systems will include Phase 1
     technology, described below, and will optionally be equipped with Phase 2
     technology should LipoMed so decide. Timing of the ordering and delivery of
     individual INCA units will be linked to development milestones as specified
     in Appendix A such that any delay in meeting or failure to meet such
     milestones shall correspondingly extend the [**] for purchase of the
     requisite INCA systems.

3.   Bruker shall be responsible for the adaptation and further development of
     its present INCA system to meet LipoMed's specifications. Bruker will not
     charge LipoMed any development costs associated with these adaptations and
     further developments, unless specifically stated below. LipoMed will assist
     Bruker with the design and testing of the Phase 1 and Phase 2 technologies.
     However, Bruker retains all commercial and patent rights (if any) for these
     developments subject to any commercial and patent rights held or applied
     for by LipoMed with respect to its NMR LipoProfile technology or otherwise
     directly related to LipoMed's proprietary methods or technologies.

4.   LipoMed and Bruker shall establish a Joint Development Team to formulate
     specifics of the development plan, including, but not limited to, project
     goals, specifications, milestones and testing. This Joint Development Team
     will consist of Drs. James Otvos and David Morgan (LipoMed), Werner Maas
     (Bruker Project Manager for INCA), and Tonio Gianotti (Bruker NMR Head of
     R&D). As needed, other individuals may be added to address specific project
     planning and execution issues.

<PAGE>

5.   LipoMed is aware that the INCA is not cleared by the U.S. FDA. LipoMed
     accepts all responsibility and costs associated with obtaining FDA (or an
     equivalent international organization's) clearance or adherence to its
     regulations. Bruker will make available any documentation needed to pursue
     this matter. It will be Bruker's responsibility to ensure that its
     equipment adheres to common international safety and quality standards as
     they relate to scientific equipment (Bruker is ISO 9001 certified and it's
     equipment meets CE standards. Bruker will promptly notify LipoMed if
     Bruker's ISO status changes or if its equipment fails to meet such CE
     standards).

6.   The INCA system is a fully functional NMR system and consists of the
     following subunits:

   .   INCA protective enclosure containing all subunits.
   .   New UltraShield II(TM) 400 MHz 54 mm magnet with lifting mechanism for
       service
   .   New, space-saving AVANCE 400 console [**].
   .   Shims, preamplifiers, [**] probe with automatic tuning capability.
   .   Pentium PC computer (complete) with NT operating system, [**], flat panel
       external LCD Touchscreen monitor and a Touchscreen NMR Interface.
   .   Unit 1 will be delivered with the NMR Case(TM) sample changer with new
       PLC controls.

7.   Bruker shall develop in Phase 1:

   .   A high capacity (More than [**] samples) automated sample delivery system
       capable of generating NMR LipoProfile data on plasma samples Less than or
       equal to [**] ml at a rate of [**] sample/[**].
   .   A new sample container format suitable for high through-put operation
       (container material, dimensions, and cost to be finalized during
       Collaboration).
   .   A means of [**] samples to the [**] prior to [**] the [**] for analysis.
   .   A modified [**] NMR probe with [**] and [**] suitable for non-spinning
       new-format samples.
   .   A modified INCA-GUI for executing automated NMR LipoProfile blood plasma
       testing, tailored for use by clinical laboratory technicians. The
       detailed specifications for this GUI will be defined by the Joint
       Development Team, with detailed input from LipoMed. Note: If LipoMed
       requires GUI software capabilities beyond those specified in advance by
       the Joint Development Team, it may develop these in-house at its own
       expense. Bruker will assist in this effort by making available to LipoMed
       on a confidential basis whatever documentation and source code is needed.
       Alternatively, LipoMed can contract with Bruker for additional software
       development services at a discounted professional services rate of $1,000
       per day, or $150 per hour, not including travel and additional expenses.

       Bruker and LipoMed agree that during the Phase 1 development effort the
       present technical concepts could be modified substantially in order to
       achieve the sample throughput, data quality and reliability required for
       LipoMed's use of INCA. Since Bruker is not equipped to handle hazardous
       biological materials (ie., blood plasma), all plasma testing will be
       conducted at LipoMed on a prototype INCA system. Testing at Bruker shall
       be restricted to suitable non-hazardous samples to be supplied by
       LipoMed. Once Phase 1 is successfully completed, development of Phase 2
       will begin.

                                        2

<PAGE>

8.   In the optional Phase 2, Bruker shall develop the following adaptations:

    .  A mechanism of transporting samples, or sample racks, to the rapid sample
       changer to enable unattended analysis of at least 300 samples, either by
       means of a new automated sample tray changer (ASTC) or any other method
       deemed suitable by the Joint Development Team.
    .  A modified GUI for executing automated NMR LipoProfile blood plasma
       testing on batches of at least 300 samples, tailored for use by clinical
       laboratory technicians. The detailed specifications for this GUI will be
       defined by the Joint Development Team, with detailed input from LipoMed.
       Note: If LipoMed requires GUI software capabilities beyond those
       specified in advance by the Joint Development Team, it may develop these
       in-house at its own expense. Bruker will assist in this effort by making
       available to LipoMed on a confidential basis whatever documentation and
       source code is needed. Alternatively, LipoMed can contract with Bruker
       for additional software development services at a discounted professional
       services rate of $1,000 per day, or $150 per hour, not including travel
       and additional expenses.

       Phase 2 will begin after Phase 1 is finished, and will take approximately
       twelve months.

9.   It is agreed that sample collection, storage, preparation, and transfer to
     the NMR measurement container, sample (or sample tray) labeling for
     unambiguous identification, sample positioning in the NMR sample tray,
     sample disposal after measurement, and commercial aspects of testing (e.g.
     patient info, billing, etc.), as well as all consumables are the sole
     responsibility of LipoMed, and are not included in the Collaboration
     Agreement.

10.  The price for each of the first [**] INCA systems sold to LipoMed,
     including items developed or adapted in Phase 1, plus installation,
     training, and a one-year warranty is $[**]. Accessory items developed or
     adapted in Phase 2 are priced at $[**] for each INCA system, including
     installation and a one-year warranty. Payment terms for the first [**]
     systems are outlined in Appendix A.

11.  The price for additional INCA systems (which include Phase 1 accessories)
     beyond the first [**] sold to LipoMed shall be negotiated, but will not
     exceed $[**] each. The price for the Phase 2 accessories shall not exceed
     $[**].

12.  In consideration for LipoMed's commitment to purchase [**] INCA systems in
     accordance with paragraph 2 of this Agreement, Bruker will not knowingly
     sell or utilize its INCA systems (or Phase 1 or Phase 2 accessories) for
     commercial use in lipoprotein and subclass analysis in the fields of
     cardiovascular disease and diabetes (the "Restricted Field") during such
     initial 36-month period. Bruker further agrees that for a period of seven
     years following such initial three-year period, it will not knowingly sell
     or utilize its INCA system for commercial use in the Restricted Field
     provided that LipoMed, including its subsidiaries, affiliates or licenses,
     purchases at least [**] additional INCA systems each year.

13.  The parties agree that upon development of the sample containers to be used
     with the rapid sample changer and agreement on the container
     specifications, they will negotiate in good

                                        3

<PAGE>

       faith a supplier agreement between LipoMed and Bruker for such sample
       containers. Provided, however, that LipoMed agrees not to reverse
       engineer Bruker proprietary sample formats which Bruker NMR develops for
       the INCA or other high-throughput NMR systems.

14.    INSTALLATION, WARRANTY AND SERVICE
       Bruker NMR remains responsible for installation, warranty service and
       post-warranty service of all INCA systems. The purchase of each INCA
       system includes one installation and demonstration of specifications by
       Bruker NMR free-of-charge. The cost of customer site preparation
       according to Bruker's site planning guide, or rigging and transportation
       of the system into the LipoMed or customer lab, and consumables required
       for the installation are not included in the Bruker NMR OEM price.
       Additional installations, if any, will be billed by Bruker NMR to LipoMed
       at normal posted service rates. Each system price includes a one-year
       limited warranty under Bruker's standard warranty terms. The period of
       warranty is one year following demonstration of specifications, but in
       any event not more than 15 months after delivery. Warranty covers both
       parts and labor. For those items supplied but not manufactured by Bruker,
       the warranty terms of the manufacturer will be transferred to the buyer.
       After the expiration of the one-year limited warranty LipoMed, or the
       final customer, may purchase additional annual Maintenance Service
       Agreements (MSA) or per-call service from the Bruker service organization
       in each country at normal MSA or per-call service rates, posted in each
       country from time to time. If a customer requires additional response
       time guarantees, or 24/7 coverage, then Bruker's standard surcharges to
       the normal MSA rates will apply.

       LipoMed will remain responsible for service issues not related to the
       automated NMR data acquisition, such as sample preparation and handling,
       administration, patient billing and data tracking.

15. GENERAL TERMS AND CONDITIONS

 15.1.   LipoMed and Bruker will jointly and by mutual agreement develop and
         release a press release and other related statements, explaining the
         benefits of this Agreement to future customers.

 15.2.   Neither party acquires any intellectual property rights under this
         Agreement except the limited rights necessary to carry out the purposes
         set forth in paragraph 12.

 15.3.   Both parties shall adhere to all applicable laws, regulations and rules
         relating to the export of technical data and equipment. LipoMed shall
         not export or re-export any Bruker product or technical data to any
         proscribed country listed in such applicable laws, regulations and
         rules unless properly authorized. Bruker shall be solely responsible
         for compliance with all applicable laws, regulations and rules relating
         to the import of equipment, parts or technology for the INCA systems.

 15.4    This Agreement does not create any agency or partnership relationship.

                                        4

<PAGE>

 15.5.   All additions or modifications to this Agreement must be made in
         writing and must be signed by both parties.

 15.6.   Drafts to this agreement were exchanged and drafted by both parties
         hereto, and accordingly this Agreement shall be considered jointly
         drafted.

 15.7    This Agreement is made under, and shall be construed according to, the
         laws of the Commonwealth of Massachusetts.

For LipoMed:                                 For Bruker:

/s/ Richard A. Franco                        /s/ Frank H. Laukien
-----------------------------------          -----------------------------------

Richard A. Franco                            Frank H. Laukien, Ph.D.
CEO, Lipomed, Inc.                           President, Bruker Instruments, Inc.

Date: 3/2/00

                                        5

<PAGE>

                                   APPENDIX A

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------

Approximate          Development                   Order/Delivery                  Payment
   Date               Milestones                      Schedule                     Schedule

-----------------------------------------------------------------------------------------------
<S>              <C>                               <C>                           <C>
[**]               Commence Phase 1 planning            [**]                      $[**] ([**]%)

                       Make [**] decision

                       Make [**] decision

[**]                                                  [**] and [**] at LM         $[**] ([**]%)

                    Determine [**] via plasma
                            [**] at LM

                   Demonstrate Phase 1 [**] at
                             Bruker

                     Develop and test [**]
[**]                                                   [**] Phase 1 [**]          $[**] ([**]%)

                    [**] Phase 1 [**] at LM

                      [**] software at LM

[**]                                               [**] Phase 1 [**] and [**]     $[**] ([**]%)

[**]               Begin Phase 2 development                  [**]                $[**] ([**]%)

[**]                                               [**] and [**] [**] with        $[**] ([**]%)
                                                         Phase 1 [**]
-----------------------------------------------------------------------------------------------

Approximate          Development                   Order/Delivery                  Payment
   Date               Milestones                      Schedule                     Schedule

-----------------------------------------------------------------------------------------------
[**]                                                            [**]              $[**] ([**]%)
[**]                                              [**]                            $[**] ([**]%)
                   Demonstrate Phase 2 [**] at
                             Bruker

                                                    [**] Phase 2 [**] for [**]    $[**]([**]%)

[**]                                                [**] and [**] [**] with       $[**]([**]%)
                                                         Phase 1  [**]
</TABLE>

                                        6

<PAGE>

[**]                   [**]                                $[**]([**]%)
[**]                       [**] Phase 2 [**] on [**]       $[**]([**]%)[**]

[**]                      [**] of Phase 2 [**] on [**]     $[**]([**]%)

[**]                       [**] with Phase 1 & 2 [**]      $[**]([**]%)

[**]                             [**] and [**]             $[**]([**]%)

[**]                   [**]                                $[**]([**]%)
[**]                       [**] with Phase 1 & 2 [**]      $[**]([**]%)

[**]                   [**] and [**]                       $[**]([**]%)

[**]                   [**] of [**]                        $[**]([**]%)

--------------------------------------------------------------------------------

                                        7<PAGE>

                                                                    Exhibit 10.7

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                               PURCHASE AGREEMENT
                                     BETWEEN
                     LIPOMED INC. OF RALEIGH, NC ("LIPOMED")
                                       AND
             BRUKER BIOSPIN CORPORATION OF BILLERICA, MA ("BRUKER")

This Purchase Agreement dated December 10, 2001 (the "Effective Date") confirms
the agreement of LipoMed to purchase and Bruker to sell [**] INCA(TM)
(Integrated NMR Clinical Analyzer) systems for LipoMed's NMR LipoProfile(R)
clinical laboratory test for blood lipoprotein levels on the terms and
conditions contained herein.

As part of this Purchase Agreement ("Agreement"), Bruker and LipoMed agree as
follows:

1. DESCRIPTION OF EQUIPMENT

   LipoMed commits to the purchase of [**] identical INCA systems, each system
   consisting of one (1) INCA and one (1) Ultra Fast Sample Changer (UFSC)
   accessory (Phase 1, outlined in the LipoMed-Bruker Collaboration Agreement of
   March 2, 2000). The Performance Specifications for the INCA unit and the UFSC
   accessory (the "Performance Specifications") are more specifically described
   in Appendix A attached hereto and incorporated herein.

   In order to avoid confusion with previously delivered INCA systems, the
   systems described under this agreement shall be designated as INCA [**]
   through INCA [**] .

   1.1. The INCA unit is configured as follows:
        1.1.1. INCA protective enclosure containing all subunits;
        1.1.2. Dedicated INCA 400 MHz 54 mm magnet with reduced magnetic stray
               field and integrated lifting and vibration control mechanism;
        1.1.3. Avance 400 console [**];
        1.1.4. Capability for automated three dimensional shimming;
        1.1.5. [**] probe compatible with the Ultra Fast Sample Changer and with
               automatic tuning capability;
        1.1.6. Pentium PC computer (complete) with Windows NT or [**] operating
               system (or Linux if available), [**], flat panel external LCD
               Touchscreen monitor and a Touchscreen NMR Interface. The minimum
               requirements for the Pentium PC computer should be at least 90%
               of the top of the line PC out at the time of delivery, and have a
               minimum of [**] Mb of memory.

Page 1 of 8

<PAGE>

     1.2. The Ultra Fast Sample Changer (UFSC) is a high capacity (>[**]
          samples), tube-based, automated sample delivery system capable of fast
          sample throughput such that sample insertion, ejection and temperature
          equilibration (to about [**]) occurs in less [**], provided that [**]
          is carried out [**] to the sample [**] the [**] for analysis. The
          total sample throughput rate is determined by the addition of the NMR
          experiment time. The Ultra Fast Sample Changer consist of:

          1.2.1. A linear transport mechanism for transporting the samples to
                 the magnet
          1.2.2. A vertical transport mechanism for inserting the samples into
                 the magnet
          1.2.3. A means of [**] samples to the [**] to [**] the [**] for
                 analysis.
          1.2.4. 500 dedicated UFSC sample tubes, [**] UFSC sample magazines and
                 80 UFSC sample tube collars.
          1.2.5. A barcode identification system for the individual sample
                 tubes. (Note that a barcode printing mechanism is not included
                 in the purchase).

2.   MISCELLANEOUS ITEMS

     As part of this agreement Bruker shall deliver in addition to the items
     mentioned above:

     2.1         Two NMR Suite licenses for an off-line data analysis ([**]
                 version).
     2.2         Two Helium transfer lines, sized for the INCA 400 magnets.

3.   DELIVERY:

     Bruker shall deliver and install [**] Integrated NMR Clinical Analyzers
     (INCA) with the Phase 1 UFSC accessory at LipoMed's facility located at
     2500 Sumner Boulevard, Raleigh, North Carolina or such other location as
     designated by LipoMed, on or before the following Specified Dates:

              [**]

     In order to meet these installation dates, Bruker will be granted
     reasonable access to the facility three weeks prior to the targeted
     installation dates. If the occupancy date of the new laboratory facility is
     delayed or if circumstances prevent LipoMed from granting Bruker access to
     the facility or providing Bruker with the reasonably necessary resources to
     commence or finish the installation, the target dates for the INCA
     installations will be extended proportionally so as to not shorten the time
     available for on-site installation. Revised installation schedules shall be
     determined in mutual agreement between LipoMed and Bruker BioSpin and
     confirmed in a written correspondence between Mr. Norwood Whitley for
     LipoMed and Dr. Werner Maas for Bruker.

     Upon execution of this Agreement, LipoMed shall issue to Bruker a Purchase
     Order for the [**] INCA systems, INCA [**] INCA [**]; provided, however,
     that such Purchase Order shall be for Bruker's administrative purposes only
     and shall not alter, expand, modify or otherwise bind the parties other
     than as set forth in this Agreement.

     LipoMed will have the right in its sole discretion to postpone delivery and
     installation of any INCA unit (the "New Installation Date"); provided,
     however, that if LipoMed delays

Page 2 of 8

<PAGE>

     delivery of any INCA, Bruker shall have the right to [**] as set forth in
     Section 5 of this Agreement if the INCA and UFSC accessory is complete and
     successfully installed on or before the New Installation Date.

4.   INSTALLATION AND ACCEPTANCE

     Installation will be considered to be complete upon demonstration by Bruker
     of the Performance Specifications to the reasonable acceptance of LipoMed
     ("Acceptance"). LipoMed will be responsible for the system validation for
     LipoProfile testing. If the UFSC is not available in time for installation
     with each INCA, Bruker shall, at its own expense, provide on a loan basis a
     complete BEST accessory [**] to enable LipoMed to partially satisfy its
     production needs, until such time as the system can be retrofit with a new
     UFSC unit. The configuration of the Best accessory shall be equal to the
     Best configurations that are currently employed at LipoMed. Upon
     availability of the UFSC unit, Bruker shall deliver and install the
     requisite number of UFSC units to LipoMed at no additional cost to LipoMed.
     Bruker agrees to use its best efforts to complete development of the UFSC
     unit in a timely manner to meet the delivery schedule set forth herein.

5.   PAYMENT

The base purchase price of each system (INCA plus Phase 1 UFSC), including
shipping, installation, and a one-year warranty, shall be $[**] (the "Base
Price"). For each system (including the UFSC) successfully installed and
Accepted on or before the Specified Date (listed above) or the New Installation
Date, as applicable, LipoMed will pay Bruker [**].

6.   PAYMENT TERMS

     [**] % of the Base Price of each INCA system on or before the thirtieth day
     prior to the applicable Specified Date or New Installation Date for such
     INCA unit
     [**] % of the Base Price on delivery and installation of each INCA unit
     [**] % of the Base Price on delivery and installation of each UFSC unit
     [**] % of the Base Price on final Acceptance of the entire INCA/UFSC
     system.
     The [**] , if applicable, shall be paid within thirty days after
     Acceptance.

7.   SERVICE AND TRAINING

     Bruker will provide up to three (3) weeks of specialized INCA/UFSC service
     training for up to 5 LipoMed employees, who will possess electrical and/or
     mechanical skills, in order to permit rapid on-site repair and maintenance
     of its [**] NMR systems in conjunction with phone support and overnight
     shipping of replacement components from Bruker. Such training will take
     place at Bruker's facilities and shall be at no additional cost to LipoMed
     (other than travel and other expenses for its employees in attendance). The
     parties will mutually agree on a time for such training. Bruker will
     provide telephone support for LipoMed employees for the repair and
     maintenance of the INCA machines. If a problem cannot be resolved over the
     phone in 24 hours, Bruker will provide the proper resources on site to have
     the unit up and running within 48 hours for the first year from
     installation of the INCA machine at issue at no charge. Subsequent to such
     first year, Bruker agrees to provide resources on site within 48 hours at
     its standard service rates.

Page 3 of 8

<PAGE>

8.   INSTALLATION, WARRANTY AND SERVICE

     Bruker is responsible for installation, warranty service and post-warranty
     service of all INCA systems. The purchase of each INCA system includes one
     installation and demonstration of specifications by Bruker. The cost of
     customer site preparation according to Bruker's site planning guide, or
     rigging and transportation of the system into the LipoMed or customer lab,
     and consumables required for the installation are not included in the
     Bruker price. Risk of loss or damage of goods during transport is on
     Bruker. All risk of loss or damage to the goods will pass to LipoMed upon
     successful delivery and installation of the goods. Each system price
     includes a one-year limited warranty under Bruker's standard warranty
     terms, following demonstration of specifications, but in any event not more
     than 15 months after delivery. Warranty covers both parts and labor. For
     those items supplied but not manufactured by Bruker, the warranty terms of
     the manufacturer will be transferred to the buyer. After the expiration of
     the one-year limited warranty LipoMed may purchase additional annual
     Service Agreements (SA) or per-call service from the Bruker service
     organization at normal SA or per-call service rates. If LipoMed requires
     additional response time guarantees, or 24/7 coverage, then a surcharge to
     the normal Service Agreement rates will apply.

     Mechanical parts of the UFSC may be subject to wear proportionally to the
     amount of measured samples. Consequently Preventative Maintenance and
     Inspection has to be performed at regular intervals, defined by the number
     of samples handled. Failure to perform these Inspections will void the
     warranty of the UFSC. The Preventative Maintenance and Inspections should
     be carried out by Bruker personnel or by LipoMed engineers, who are trained
     by Bruker. Parts that need replacement due to wear are considered
     consumables and are not covered under the warranty agreement.

     LipoMed will remain responsible for service issues not related to the
     automated NMR data acquisition, such as sample preparation and handling,
     administration, patient billing and data tracking.

9.   GENERAL TERMS AND CONDITIONS

     9.1. DISCLAIMER: LipoMed is aware that the INCA is not cleared by the U.S.
          FDA. LipoMed accepts all responsibility and costs associated with
          obtaining FDA (or an equivalent international organization's)
          clearance or adherence to its regulations. Bruker will make available
          any INCA-related documentation needed to pursue this matter. It will
          be Bruker's responsibility to ensure that its equipment adheres to
          common international safety and quality standards as they relate to
          scientific equipment (Bruker is ISO 9001 certified and its equipment
          meets CE standards. Bruker will promptly notify LipoMed if Bruker's
          ISO status changes or if its equipment fails to meet such CE
          standards).

     9.2. INDEMNIFICATION. Bruker shall defend and indemnify and hold LipoMed
          harmless and its directors, officers, employees and agents against any
          claims, suits, actions,liabilities, losses, cost, expenses (including
          reasonable attorney's fees), judgments or damages suffered or incurred
          by them resulting from (i) any act or omission of Bruker or its
          officers, employees and agents; (ii) any breach by Bruker of

Page 4 of 8

<PAGE>

       any provision of this Agreement; or (iii) the proper operation or use of
       the INCA unit and/or UFSC accessory by LipoMed or any third party.

9.3.   LIMITATION OF LIABILITY. In no event shall LipoMed be liable for special,
       incidental, indirect, consequential exemplary or punitive damages or lost
       profits even if LipoMed is told that any such damages may occur.

9.4.   LipoMed and Bruker will jointly and by mutual agreement develop and
       release a press release describing this purchase.

9.5.   LipoMed hereby grants to Bruker [**] the supply of the UFSC NMR sample
       tubes, magazines, racks, collars and related consumables to LipoMed. The
       parties agree to [**] from the commencement [**]. The parties may extend
       the [**] by mutual written consent. If the parties have not reached an
       agreement by the expiration of the [**], LipoMed shall have the right to
       terminate [**] in its sole discretion. LipoMed agrees not to reverse
       engineer Bruker's proprietary sample formats which Bruker develops for
       the INCA or other high-throughput NMR systems.

9.6.   Neither party acquires any intellectual property rights under this
       Agreement other than any licenses which may be included in the NMR Suite
       software or any other software delivered in accordance with this
       Agreement.

9.7.   Both parties shall adhere to all applicable laws, regulations and rules
       relating to the export of technical data and equipment. LipoMed shall not
       export or re-export any Bruker product or technical data to any
       proscribed country listed in such applicable laws, regulations and rules
       unless properly authorized. Bruker shall be solely responsible for
       compliance with all applicable laws, regulations and rules relating to
       the import of equipment, parts or technology for the INCA systems.

9.8.   This Agreement does not create any agency or partnership relationship.

9.9.   Neither LipoMed nor Bruker shall be responsible for delays or failures to
       perform their respective duties and obligations hereunder to the extent
       that such delays or failures result from acts of God, strikes, lockouts,
       riots, war, epidemics, governmental regulations imposed after the
       Effective Date, fire, power failures, earthquakes, other natural elements
       or any other act beyond such party's reasonable control.

9.10.  All additions or modifications to this Agreement must be made in writing
       and must be signed by both parties.

9.11.  Drafts to this agreement were exchanged and drafted by both parties
       hereto, and accordingly this Agreement shall be considered jointly
       drafted.

9.12.  This Agreement is made under, and shall be construed according to, the
       laws of the Commonwealth of Massachusetts.

Page 5 of 8

<PAGE>

       9.13.  In consideration for the purchase by LipoMed of the INCA
              machines pursuant to the Collaboration Agreement between LipoMed
              and Bruker dated March 2, 2000 and the commitment of LipoMed to
              purchase the [**] INCA machines as set forth herein, Bruker will
              not sell its INCA systems (including Phase 1 or Phase 2
              accessories (as described in the Collaboration Agreement)) for
              commercial use in lipoprotein and subclass analysis in the fields
              of cardiovascular disease, insulin resistance and diabetes (the
              "Restricted Field") for a period of seven (7) years from the
              Effective Date. Subsequent to such seven (7) year period, Bruker
              further agrees that so long as LipoMed, its subsidiaries,
              affiliates or licensees purchase a combined total of at least [**]
              additional INCA systems per year, it will not sell its INCA system
              for commercial use in the Restricted Field. Notwithstanding the
              foregoing, if LipoMed licenses its proprietary software (the
              "LipoMed Software") to a third party for use in the Restricted
              Field and permits such third party to acquire the NMR LipoProfile
              on an NMR system other than the INCA, then Bruker will have the
              right to sell its INCA system to such third party solely for use
              with the LipoMed Software. This Section 9.13 shall amend and
              supersede in its entirety Section 12 of that Collaboration
              Agreement dated March 2, 2000 between LipoMed and Bruker (the
              "Collaboration Agreement"). Except as herein amended, the terms
              and provisions of the Collaboration Agreement shall remain in
              full force and effect as originally executed.

10.    TERMINATION

       10.1   This Agreement may be terminated:
              i)   By mutual agreement in writing of LipoMed and Bruker;
              ii)  By either party upon notice to the other in the event that
              the other party shall dissolve, shall file or have filed against
              it a petition in bankruptcy (which is not dismissed within sixty
              (60) days after it is filed), or shall make an assignment for the
              benefit of its creditors;
              iii) By either party, upon thirty (30) days' notice to the other,
              in the event that the other party commits a material breach of
              this Agreement and fails to cure such breach within the said
              thirty (30) days.

       10.2   Termination of the Agreement shall not entitle Bruker to any
              termination or severance compensation or to any payment in respect
              to any goodwill established by Bruker during the term of this
              Agreement or render LipoMed liable for damages on account of the
              loss of prospective profits or on account of any expenditure,
              investment or obligation incurred or made by Bruker.

       10.3   Termination of the Agreement shall not entitle LipoMed to any
              termination or severance compensation or to any payment in respect
              to any goodwill established by LipoMed during the term of this
              Agreement or render Bruker liable for damages on account of the
              loss of prospective profits or on account of any expenditure,
              investment or obligation incurred or made by LipoMed.

Page 6 of 8

<PAGE>

For LipoMed:                               For Bruker:

/s/James Otvos                             /s/ Werner E. Maas
------------------------                   -------------------------------------

James Otvos, Ph.D.                         Werner E. Maas, Ph.D

Chief Scientific Officer, LipoMed, Inc.    Vice-President, Bruker BioSpin, Corp.

Date:  12/10/01                            12/12/01

Page 7 of 8

<PAGE>

                                  APPENDIX A

     PERFORMANCE SPECIFICATIONS

     1.   SAMPLE DEFINITION
          Specifications shall be demonstrated on a TMA-standard contained in a
          UFSC sample tube. The TMA-standard has the following make-up: 15mM
          trimethyl acetic acid, 5mM disodium EDTA, 3mM calcium chloride, 120mM
          potassium chloride, 10% v/v deuterium oxide and pH balanced at 9.0.

     2.   PROBE:
            -   Proton [**] pulse length less than [**] microseconds;
            -   Non-spinning lineshape on a 3% CHCl\\3\\/d-Acetone sample better
                than 1/8/14 Hz at 50/0.55/0.11 % of the chloroform proton
                resonance;
            -   Linewidth on TMA less than [**];
            -   Signal to noise (S/N) greater than [**]:1 on standard TMA
                samples. Experimental conditions: [**]

      3.  UFSC:
            -   Ability to run greater than [**] samples unattended;
            -   Sample [**] capability;
            -   Sample insertion, ejection and [**] in less than [**] devoid of
                [**] gradient across the measurement volume, with [**] carried
                out in the UFSC [**] to the sample [**] the [**] for analysis.
                [**] requires a [**] in the [**] of approximately [**],
                depending  on the [**] of the magazine and samples.

      4.  SYSTEM:
            -   Ability to automatically perform a [**] at the beginning of a
                run and at regular intervals during the course of operation;
            -   Automatic shimming capability at the beginning of the run and
                as needed;
            -   Data must be processed during experiment for quality control
                purposes;
            -   [**] should be regulated to within [**].

ACCEPTANCE PROTOCOL

     1.   Bruker will install the equipment and demonstrate lineshape, pulse
          length and sensitivity requirements as described above.
     2.   Lipomed will load their software on the machine within 24 hours after
          the installation and run [**] standard TMA samples. These samples will
          be evaluated for the following criteria:
               a. sample throughput
               b. lineshape: variation of TMA linewidth at half height less than
                  [**]%;
               c. reproducibility: integrated intensities of [**] with [**] of
                  [**] less than [**]%.

Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]